49 related articles for article (PubMed ID: 34927308)
1. Relapse recovery in relapsing-remitting multiple sclerosis: An analysis of the CombiRx dataset.
Koch MW; Moral E; Brieva L; Mostert J; Strijbis EM; Comtois J; Repovic P; Bowen JD; Wolinsky JS; Lublin FD; Cutter G
Mult Scler; 2023 Dec; 29(14):1776-1785. PubMed ID: 37830451
[TBL] [Abstract][Full Text] [Related]
2. Predictors of Ocrelizumab Effectiveness in Patients with Multiple Sclerosis.
Cellerino M; Boffa G; Lapucci C; Tazza F; Sbragia E; Mancuso E; Bruschi N; Minguzzi S; Ivaldi F; Poirè I; Laroni A; Mancardi G; Capello E; Uccelli A; Novi G; Inglese M
Neurotherapeutics; 2021 Oct; 18(4):2579-2588. PubMed ID: 34553320
[TBL] [Abstract][Full Text] [Related]
3. Association of No Evidence of Disease Activity With No Long-term Disability Progression in Multiple Sclerosis: A Systematic Review and Meta-analysis.
Rotstein D; Solomon JM; Sormani MP; Montalban X; Ye XY; Dababneh D; Muccilli A; Shah P
Neurology; 2022 Jul; 99(2):e209-e220. PubMed ID: 35473761
[TBL] [Abstract][Full Text] [Related]
4. Recruitment of participants to a multiple sclerosis trial: the CombiRx experience.
Bhanushali MJ; Gustafson T; Powell S; Conwit RA; Wolinsky JS; Cutter GR; Lublin FD; Cofield SS
Clin Trials; 2014 Apr; 11(2):159-66. PubMed ID: 24686106
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of 2-year "No evidence of disease activity" (NEDA-3 and NEDA-4) in relapsing-remitting multiple sclerosis. A real-world study.
Bazzurri V; Fiore A; Curti E; Tsantes E; Franceschini A; Granella F
Mult Scler Relat Disord; 2023 Nov; 79():105015. PubMed ID: 37769430
[TBL] [Abstract][Full Text] [Related]
6. Clinical and radiological consequences of delayed therapy escalation in patients with relapsing-remitting multiple sclerosis.
Popiel M; Bartosik-Psujek H
Neurol Neurochir Pol; 2024; 58(1):84-93. PubMed ID: 38112646
[TBL] [Abstract][Full Text] [Related]
7. CSF levels of Chitinase3like1 correlate with early response to cladribine in multiple sclerosis.
Marastoni D; Foschi M; Eccher C; Crescenzo F; Mazziotti V; Tamanti A; Bajrami A; Camera V; Ziccardi S; Guandalini M; Bosello F; Anni D; Virla F; Turano E; Romoli M; Mariotti R; Pizzini FB; Bonetti B; Calabrese M
Front Immunol; 2024; 15():1343892. PubMed ID: 38404586
[TBL] [Abstract][Full Text] [Related]
8. MicroRNAs Associated with Disability Progression and Clinical Activity in Multiple Sclerosis Patients Treated with Glatiramer Acetate.
Casanova I; Domínguez-Mozo MI; De Torres L; Aladro-Benito Y; García-Martínez Á; Gómez P; Abellán S; De Antonio E; Álvarez-Lafuente R
Biomedicines; 2023 Oct; 11(10):. PubMed ID: 37893133
[TBL] [Abstract][Full Text] [Related]
9. Altered cerebrospinal fluid neurofilament light chain but not neurogranin levels are associated with response to ocrelizumab treatment in relapsing remitting multiple sclerosis: a preliminary study.
Kızılay T; Akbayir E; Erol R; Demir AS; Özkan Yaşargün D; Yilmaz V; Tuzun E; Turkoglu R
Eur Neurol; 2024 May; ():. PubMed ID: 38754397
[TBL] [Abstract][Full Text] [Related]
10. Autologous hematopoietic stem cell transplantation is superior to alemtuzumab in patients with highly active relapsing multiple sclerosis and severe disability.
Vaisvilas M; Kaubrys G; Kizlaitiene R; Taluntiene V; Giedraitiene N
Mult Scler Relat Disord; 2023 Dec; 80():105096. PubMed ID: 37949024
[TBL] [Abstract][Full Text] [Related]
11. Disability Progression in Multiple Sclerosis Patients using Early First-line Treatments.
Lefort M; Vukusic S; Casey R; Edan G; Leray E;
Eur J Neurol; 2022 May; 29(9):2761-71. PubMed ID: 35617144
[TBL] [Abstract][Full Text] [Related]
12. Harmonizing Definitions for Progression Independent of Relapse Activity in Multiple Sclerosis: A Systematic Review.
Müller J; Cagol A; Lorscheider J; Tsagkas C; Benkert P; Yaldizli Ö; Kuhle J; Derfuss T; Sormani MP; Thompson A; Granziera C; Kappos L
JAMA Neurol; 2023 Nov; 80(11):1232-1245. PubMed ID: 37782515
[TBL] [Abstract][Full Text] [Related]
13. Towards the implementation of 'no evidence of disease activity' in multiple sclerosis treatment: the multiple sclerosis decision model.
Stangel M; Penner IK; Kallmann BA; Lukas C; Kieseier BC
Ther Adv Neurol Disord; 2015 Jan; 8(1):3-13. PubMed ID: 25584069
[TBL] [Abstract][Full Text] [Related]
14. High frequency of circulating non-classical monocytes is associated with stable remission in relapsing-remitting multiple sclerosis.
Minote M; Sato W; Kimura K; Kimura A; Lin Y; Okamoto T; Takahashi R; Yamamura T
Immunol Med; 2024 Mar; ():1-15. PubMed ID: 38539051
[TBL] [Abstract][Full Text] [Related]
15. Progression Independent of Relapse Activity in Multiple Sclerosis: Closer to Solving the Pathologic Puzzle.
Tur C; Rocca MA
Neurology; 2024 Jan; 102(1):e207936. PubMed ID: 38165383
[TBL] [Abstract][Full Text] [Related]
16. About the Editor: Neda Laiteerapong, MD, MS: Using Economic Modeling to Improve Access to Care.
Page B
Diabetes Care; 2024 May; 47(5):766-767. PubMed ID: 38640408
[No Abstract] [Full Text] [Related]
17. Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis.
Gonzalez-Lorenzo M; Ridley B; Minozzi S; Del Giovane C; Peryer G; Piggott T; Foschi M; Filippini G; Tramacere I; Baldin E; Nonino F
Cochrane Database Syst Rev; 2024 Jan; 1(1):CD011381. PubMed ID: 38174776
[TBL] [Abstract][Full Text] [Related]
18. Early first-line treatment response and subsequent disability worsening in relapsing-remitting multiple sclerosis.
Koch MW; Mostert J; Repovic P; Bowen JD; Wolinsky JS; Lublin FD; Strijbis E; Cutter G
Eur J Neurol; 2022 Apr; 29(4):1106-1116. PubMed ID: 34927308
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the EDSS, Timed 25-Foot Walk, and the 9-Hole Peg Test as Clinical Trial Outcomes in Relapsing-Remitting Multiple Sclerosis.
Koch MW; Mostert JP; Wolinsky JS; Lublin FD; Uitdehaag B; Cutter GR
Neurology; 2021 Oct; 97(16):e1560-e1570. PubMed ID: 34433679
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
